The Hemopoietic Stem Cell Niche Versus the Microenvironment of the Multiple Myeloma-Tumor Initiating Cell by Zipori, Dov
REVIEW PAPER
The Hemopoietic Stem Cell Niche Versus
the Microenvironment of the Multiple Myeloma-Tumor
Initiating Cell
Dov Zipori
Received: 6 December 2009 /Accepted: 29 December 2009 /Published online: 5 February 2010
# The Author(s) 2010. This article is published with open access at Springerlink.com
Abstract Multiple myeloma cells are reminiscent of hemo-
poietic stem cells in their strict dependence upon the bone
marrow microenvironment. However, from all other points of
view, multiple myeloma cells differ markedlyfrom stemcells.
The cells possess a mature phenotype and secrete antibodies,
and have thus made the whole journey to maturity, while
maintaining a tumor phenotype. Not much credence was
given to the possibility that the bulk of plasma-like multiple
myeloma tumor cells is generated from tumor-initiating cells.
Although interleukin-6 is a major contributor to the formation
of the tumor’s microenvironment in multiple myeloma, it is
not a major factor within hemopoietic stem cell niches. The
bone marrow niche for myeloma cells includes the activity of
inflammatory cytokines released through osteoclastogenesis.
These permit maintenance of myeloma cells within the bone
marrow. In contrast, osteoclastogenesis constitutes a signal
that drives hemopoietic stem cells away from their bone
marrow niches. The properties of the bone marrow microen-
vironment, which supports myeloma cell maintenance and
proliferation, is therefore markedly different from the charac-
teristics of the hemopoietic stem cell niche. Thus, multiple
myeloma presents an example of a hemopoietic tumor
microenvironment that does not resemble the corresponding
stem cell renewal niche.
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Introduction
Multiple myeloma (MM) is a human malignancy first
reported approximately 160 years ago. It apparently
initiates by over proliferation of plasma cells, a status
called monoclonal gammopathy of undetermined signifi-
cance (MGUS), that may progress to overt MM in which
tumor plasma cells accumulate within the bone marrow
microenvironment, causing a bone destructive disease
(reviewed by [1–8]). The bone marrow localization of
these tumor cells is a most characteristic feature of MM,
and it is only at the very late stages of the disease, that the
tumor cells may disseminate to other locales. Several drugs,
and various other therapeutic modes, such as antibodies to
cell surface markers of the tumor cells, are used in the clinic
to reduce the disease symptoms (reviewed by [9]. An
example is the use of a single-chain Fv against leukocyte
antigen-A that causes myeloma cell death [10]. An effective
cure for MM is still lacking thereby calling for further
investigations into the nature of this disease.
The specific bone marrow localization of MM is
reminiscent of the strict dependence of the precursors of
plasma cells, i.e., the hemopoietic stem cells (HSCs), upon
specific bone marrow niches. This goes along with the
cancer stem cell (CSC) theory dealing with heterogeneity
among the tumor cell populations (reviewed in [11–36]). It
is argued that most cells in the tumor are comparable to
mature normal cell counterparts; these “mature” tumor cells
are incapable of initiating new tumor formation upon
isolation and transplantation into susceptible recipients.
By the same token, mature blood cells would be incapable
of engraftment and of the establishment of a new bone
marrow structure. In contrast, a minor cell population
within the tumor, consists of highly proliferating cells
capable of tumor formation upon transplantation. These are
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DOI 10.1007/s12307-009-0034-7said to be the CSCs based on their rareness, possession of
cell surface markers similar to their normal counterpart
stem cells and by their superior ability to form tumors. This
latter function is regarded as the tumor corollary of the
ability of the normal HSCs to create a new hemopoietic
tissue in animals or humans deficient in this tissue. The
analogy made by many investigators, between tumor
formation on the one hand, and normal tissue regeneration
on the other, seems somewhat exaggerated: normal tissue
generation is accurately programmed and is restricted to
embryonic life, while tumor formation is highly chaotic,
and may occur throughout the entire life span. These
processes, therefore, have little in common. However, in
this review, the CSC theory will be taken as is, and the
question dealt with below is whether CSCs occur in MM or
whether they are absent from this disease.
Several reports show that cellular heterogeneity exists in
MM. Only rare cells, within mouse plasmacytoma cell
lines, formed tumors upon transplantation [37–41]. Simi-
larly, in vitro analysis of primary MM cells indicated a low
incidence of clone forming cells [42]. Thus, the heteroge-
neous MM population contains some rare clonogenic cells
that, at least in vitro, show high proliferation potential.
More importantly these cells were capable of recreating the
disease in recipient immunodeficient animals [38, 40].
Although the human-to-mouse transplantation model is
widely used [43] it is unclear how much it represents a
true corollary of the human disease (commented on by
[44]). Indeed, human MM has an immune component
which is of importance [45], and many cytokines that may
have relevance to MM, do not operate effectively across
species barriers. From this viewpoint, a 3 dimensional
reconstruction of the MM microenvironment ex vivo might
prove as informative [46]. The data derived from in vitro
and in vivo studies on clonogenic and transplantable MM
cells show nevertheless that MM contains a tumor-initiating
cell (TIC) component (Box-1). Are these TICs, the MM
CSCs? One way to define CSCs is to purify them on the
basis of surface marker expression. Such an approach
suggested that the putative MM CSCs are CD138
−/CD20
+
[39]. However, cells capable of transferring the disease
were found also in the CD138
+ population as well as in the
side population (SP) (Commented on by [47]). Whereas the
MM TICs were reported to reside within the CD34
+
population of hemopoietic progenitors [40], other claims
relate these cells to the memory B cell population [48, 49].
It is therefore clear, at this point, that marker expression is
not a reliable means of identifying CSCs or TICs with any
degree of certainty. This is in fact true in the case of all
stem cell type (reviewed by [50, 51]). The findings that
most plasma tumor cells are capable of forming tumors in
immunodeficient mice, when the appropriate conditions are
provided [52, 53] are more dramatic. According to these
findings, the rareness of TICs, which is often compared to
the low incidence of normal HSCs found in the bone
marrow, is just apparent. A high incidence of tumor-
forming cells in the cancerous population has been reported
[54]. It is probable that TICs seem rare in some assays
because of the harsh conditions used that allow only some
of the TICs to express their tumor forming potential.
Box-1 
 
Human tumor-initiating cells are often defined as the cells, within an established 
tumor or a cultured tumor cell line, endowed with a clonogenic capacity in vitro. 
Herein, a more critical definition is preferred and relates to the capacity of cells,  to 
transfer the disease to immunodeficient animals upon transplantation. The result of 
this transplantation must be the formation of a tumor, in the mouse, which is of 
human origin and the disease must share some features with the corresponding human 
cancer. 
One important point of note is that high proliferation
potential is not a HSC property. The latter renew very
slowly and their division is a rare event [55]. This
constitutes one major difference between HSCs and
clonogenic MM cells. Colony formation in culture is
mostly a committed hemopoietic progenitor property.
Progenitors do proliferate extensively, but transiently. This
is in sharp contrast to HSCs that do not proliferate
extensively and perform only rare self-renewal divisions.
Therefore the in vitro clonogenic cells differ markedly from
HSCs and whether they are identical to in vivo TICs or
CSCs is questionable. Although high in vitro proliferation
capacity is often regarded as a cancer stem cell property
(reviewed by [48, 49, 56]), the link between this property
16 D. Ziporiand the capacity to form tumors is not apparent. The CSC
theory is not further analyzed within this review, whereas
the similarity/difference between MM TICs versus normal
HSCs is examined in detail. The normal HSC in its niche is
described first, followed by an analysis of the MM TIC in
its bone marrow microenvironment. It is argued that these
two cell types and their corresponding microenvironments
have little in common.
It is of great importance that a distinction between stem
cell niches in particular, and microenvironments in general
(Box-2) be made. The microenvironment of an organ
contains a wide range of different domains. Some of these
are designed to support differentiation, others promote
release from the bone marrow compartment and only the
highly specialized and rare ones are designed to support
stem cell renewal. The latter are designated as the “stem
cell niches” (Fig. 1). The function of the stem cell niche is
to maintain the stem cell phenotype. The release of the stem
cell from the niche will result in differentiation. The terms
“niche” and “microenvironment” are often interchangeable
in the literature related to stemness. One example is the
definition of the niche as an entity essential for survival,
growth and differentiation [57]. Clearly, stem cell niches
are engaged in antagonism with differentiation rather than
with promotion of this process [58–60]. Differentiation
inducing domains should therefore not be confused with
stem cell maintenance niches. Thus, HSC niches are
defined herein as the specific locals within the bone
marrow microenvironment, which specialize in mainte-
nance of stem cells in their undifferentiated state.
The Hemopoietic Stem Cell in its Bone Marrow Niche
Hemopoiesis occurs in the bone marrow, within the bone
cavity, wherein the hemopoietic cells and their descendents
are engulfed and compartmentalized by a microenviron-
mental tissue composed of various cell types. This is
referred to collectively as the bone marrow stroma. Cells
that belong in this category are mesenchymal cells (such as
adipocytes and adventitial cells) endothelial cells and some
derivatives of the HSC, such as macrophages. The bone
marrow stroma is apparently vital for the normal function-
ing of HSCs. The latter cells depend on the stroma for their
renewal and differentiation. It is noteworthy, that most
experimental data that demonstrate the functions of stromal
cells, have been obtained from in vitro studies. Nonethe-
less, in vivo observations demonstrated close proximity
between hemopoietic cells of immature phenotype and
stromal elements, strongly supporting the importance of the
stroma in the maintenance and regulation of hemopoiesis.
Although not as solid as epithelial organs, the bone
marrow is a well-organized tissue. In the former, cell
contacts are enforced by junctional complexes that tightly
bind one cell to another. In contrast, within the bone
marrow, cells interact through adhesion molecules but are
not tightly bound. Hemopoietic cells are capable of
intensive motion and migration, within the bone marrow
proper, and also migrate back into it from the blood. The
bone marrow is nevertheless well organized into distinct
compartments, due to the meshwork of stromal cells. The
stroma, including the vasculature forms a sponge-like
structure attached to the trabecular bone projections, serves
both a structural as well as a regulatory function. The
localizationofstemcellswithinthebonecavityisnotrandom.
It has been shown, by use of histological examination of the
bone marrow following depletion, that foci of hemopoiesis
first appear at endosteal and periarteolar sites [61]. These
Fig. 1 The general structure of the HSC niche: Self-renewal divisions
occurs as long as the stem cell remains within the niche a. Detachment
from the niche and departure into other microenvironmental domains
result in differentiation b
Myeloma microenvironment versus stem cell niche 17morphological studies implied that stem cells reside in the
specific regions mentioned above, and following injury they
start proliferating to supply new mature cells. It was later
found that HSCs are specifically localized to the region close
to the endosteal bone that was termed the stem cell niche
[62, 63].
Box-2 
 
A strict distinction is made herein between the terms “niche” and, 
“microenvironment”; these terms are often used interchangeably in the literature 
related to stem cell biology. The “stem cell niche” in the sense used herein, means the 
physical-chemical entity that provides minimal requirements for the survival, and 
often self-renewal of stem cells. This term does not include other tissue domains in 
which stem cells may reside transiently while undergoing a process of differentiation. 
Such sites are referred to as “differentiation domains”. The term “microenvironment”, 
used herein, includes all the variety of domains existing within a specific tissue. Thus, 
when the term microenvironment is mentioned with regard to MM cells, it refers to 
the fact that MM cells reside within the bone marrow at large, and may be found in a 
rather widespread pattern crossing different specific bone marrow domains, as tumor 
cells often do. 
 
 
One major constituent of the bone marrow stroma is the
mesenchymal tissue. These cells are mostly defined through
elimination, in lacking properties of well-defined cells such
as hemopoietic, epithelial, neuronal, and endothelial cells.
The mesenchyme does not exhibit a specific gene set that
may be used practically to identify the cells belonging to
this category in vivo. Their identification in culture relies
on their adhesion, fibroblast-like morphology and migrato-
ry properties. In vitro propagation of mesenchymal cells
from bone marrow origin and their re-introduction in vivo
demonstrated the capacity of these cells to create a local
ectopic stromal structure that induces the homing of HSCs
and the subsequent initiation of active hemopoiesis; in vitro
seeding of bone marrow cells from guinea pigs resulted in
death of the hemopoietic cells and growth of adherent
fibroblastoid cells. These cells were suggested to be
representatives of the bone marrow microenvironment
stromata [64]. The transplantation of these cells, under the
kidney capsule of recipient guinea pigs, resulted in the
formation of bone structures containing hemopoietic cells.
Whereas the bone was found to be of donor fibroblast
origin, the hemopoietic cells within the bone structure were
of recipient origin [65]. Single cells isolated from fibro-
blastoid colonies were recently shown to form bone
structures in vivo in which hemopoiesis occurred [66].
Co-culture of bone marrow fibroblasts, with freshly isolated
hemopoietic cells, results under specific in vitro conditions,
in long-term hemopoiesis [67]. Overall, the in vitro culture
experiments, taken together with the in vivo findings and
morphological observations on the bone marrow structure,
suggest that the mesenchymal component of the bone
marrow, significantly contributes to the formation of the
hemopoietic microenvironment and particularly to the
maintenance of the HSC pool. These cells may therefore
contribute to the formation of the HSC niche.
The implications of the above studies found support in
recent experiments in which the bone marrow niche of HSCs
was investigatedinvivo.Itwas foundthat HSCsresideinthe
endosteal region in the proximity of osteoblastic cells [68].
HSCs were also found in vascular niches [69]. The niche of
normal HSCs seems therefore to be made either of
osteoblasts or alternatively endothelial cells, reticular
adventitial cells or all of these cells. It is unclear whether
the above cell types constitute different entities, or whether
they are all derivatives of mesenchymal cells.
A long list of molecules is supposed to contribute, in
varying degrees, to the stem cell maintaining capacity of
the HSC niche. These include adhesion molecules such as
N-candherin [70], very late antigen-4 (VLA-4) [71]) and
vascular cell adhesion molecule-1 (VCAM-1) [72]. Hor-
mones and growth factors have been similarly implicated
including parathyroid hormone acting through its bone
18 D. Ziporimarrow receptors [68], osteopontin [73], bone morphogenic
protein (BMP) [74], stromal derived factor-1 (SDF-1) and
its receptor CXCR4 [75], angiopoietin through its receptor
Tie-2 [76], Wnt pathway activation [77], thrombopoietin
and its receptor Mpl [78], stem cell factor and its receptor
cKit [79], insulin-like growth fctor2 [80], and other factors
(reviewed by [81, 82]). The relative contribution of each of
the above to niche formation is not completely understood.
It is however obvious that stem cell maintenance requires a
plethora of signals, rather then a single putative “stem cell
renewal factor”, which has been pursued for decades.
The Restrictive Nature of Stem Cell Niches
Notably, several of the factors that emanate from the stem
cell niche, listed above as regulators of HSCs, operate in a
restrictive manner and do not promote growth. They are
often referred to as negative regulators or inhibitors. Earlier
attempts to induce in vitro HSC growth, involved a long list
of conditions that failed to allow survival of HSCs and their
subsequent long-term proliferation. The long-term bone
marrow cultures, in which fresh bone marrow is seeded
onto pre-formed confluent stromal cell layers, demonstrated
the importance and requirement of the stroma for continued
hemopoiesis. The combination of stromal cell layers, with
hemopoietic colony assays in semisolid medium, allowed
the investigation of the events that occur at a single colony
forming cell level. The fate of the hemopoietic progenitors
in such co-cultures was determined by the stromal cells;
hemopoietic colony formation was suppressed by the
stroma, and instead of large colonies containing differenti-
ated cells, micro clusters of progenitors emerged. The
presence of stroma overrides the effect of cytokines that are
needed for colony formation. Separation of the hemopoietic
cells from the stroma, by an agar layer, leads to the effect of
the stroma being abolished [58, 59]. Thus, the proximity of
the hemopoietic progenitor cell, to the stroma, represses the
capacity of cytokines to induce differentiation and, thereby
allowing by default, the maintenance of the undifferentiated
cells [51]). These experiments suggested, for the first time,
that the stroma protects HSCs from differentiation [83]b y
antagonizing with the function of differentiation-inducing
cytokines. The differentiation restraining activity was
ascribed to members of the transforming growth factor
(TGF) β family, which are differentiation antagonists [84,
85]( F i g .2). The latter family in addition to other
molecules, were all proposed to take part in the formation
of bone marrow stem cell niches.
The role of differentiation antagonists, in the creation of
stem cell niches, has now been well established through
studies of Drosophila Melanogaster [60]. Both the gonadal
stem cells and the niche cells can be morphologically
identified in situ. This is completely different from
mammalian HSCs, and in fact differs from all other
mammalian stem cell systems, which are hard to detect
and do not have specific markers that identify them
unequivocally. The outstanding advantage of Drosophila
stem cells, in being morphologically conspicuous assisted
in identifying factors that maintain stem cells in an
undifferentiated state within their niche. First and foremost,
the direct contact of the stem cell with the niche cell is
obligatory. The second requirement is the activity of
decapentaplegic (Dpp), the Drosophila homologue of the
TGFβ molecule bone morophogenic protein (BMP). Dpp
antagonizes the activity of bag of marbles (BOM), which is
a differentiation factor, enabling the maintenance of stem
Fig. 2 The mechanism of HSC maintenance within its niche, in an
undifferentiated form: Differentiation antagonists such as TGFβs,
block the capacity of the HSC to respond to differentiation inducing
cytokines a. Detachment from the niche releases the stem cell from the
effect of the antagonist b
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hemopoietic cells and the later on gonadal cells of the fruit
fly, taken together, strongly suggest that the stem cell niche
provides antagonism with differentiation. This is mediated
through molecules such as TGFβs, thereby protecting stem
cells from overdifferentiation, and directing self-renewal by
default.
The Stem Cell Niche and the Stem State
It thus appears that a niche cell forms a platform for the
adhesion of the stem cell. Physical separation from the
niche allows the stem cells to react to differentiation factors.
In Drosophila, divisions of stem cells that occur while the
spindle is perpendicular to the niche, leave one stem cell
adherent to the niche. This cell maintains its stemness. The
other cell is detached from the niche and starts a
differentiation process. However, when such a cell is forced
back into the niche, it reassumes a stem cell fate [86]
(Fig. 3). Thus, at least in Drosophila, de-differentiation
occurs and stem cells may be born out of differentiating
cells and not only through self-renewal, as hypothesized for
HSCs. Does de-differentiation occur in mammalians?
Several publications suggest this option [87–89]. In view
of the great similarities between stem cell niches in
organisms including plants, Drosophila and mammalians,
de-differentiation in mammalians is a realistic possibility
which leads to the suggestion that stemness in mammalians,
represents a reversible state in the life cycle of the cell [50,
51]. This view is compatible with the ease by which mature
cells may be reprogrammed. The reprogramming of skin
fibroblasts, liver and gut cells and B lymphocytes, requires
the forced expression of 3-4 genes [90–93] whereas the de-
differentiation of neuronal stem cell into induced pluripo-
tent cells requires the overexpression of oct-4 and Klf4 only
[94]. More dramatic is the reprogramming of spermatogo-
nia that occurs spontaneously upon culture without the need
for forced expression of exogenously introduced genes
[95].
The Bone Marrow Microenvironment of MM
Tumor-Initiating Cells
The bone marrow microenvironment is supportive of cells
that apparently do not belong there, such as, metastasizing
cells of small lung cell carcinoma, breast carcinoma and
prostate tumors. In addition to these remote tumors, the
bone marrow microenvironment is a site for the develop-
ment and maintenance of MM. This bone marrow locali-
zation is a fundamental characteristic of MM. Most stages
of the disease occur within the bone marrow while
dissemination to other tissues and organs is a late
occurrence in this disease. It is inferred that the bone
marrow microenvironment is required for the development
of MM, and that the MM tumor cells, are dependent upon
stromal elements of the bone marrow compartment. It has
further been suggested that MM cells utilize for their
survival and proliferation, molecular cues provided by the
bone marrow environment, that are similar to those
supporting normal stem cell growth and differentiation.
This statement is however hypothetical; it is still not
entirely clear what are the molecular cues that the stroma
elaborate, which affect hemopoiesis in vivo, both in the
case of normal stem cells and in the case of MM cells.
An additional characteristic feature of MM is the
increased osteolytic activity, leading to the high incidence
of bone fractures. Bone homeostasis is maintained normally
by two opposing activities. Osteoblasts build bone by
depositing extracellular-matrix that undergoes mineralization.
Fig. 3 De-differentiation in Drosophila gonads: The gonadal stem cell
(GSC) that remain attached to their niche following division, remain
undifferentiated (I) whereas they differentiate upon release from the
niche (I). GSC de-differentiate upon return to the niche (II)
20 D. ZiporiOsteoclasts degrade bone structures by creating a sealing
zone into which they release protons and proteases that
dissolve the mineral and proteins. The balance between
bone formation by osteoblasts and degradation by
osteoclasts, results in normal bone remodeling and
maintenance of an intact bone structure. It is believed
that MM cells cause bone damage by inducing osteo-
clastogenesis and by diminishing osteogenic functions.
Evidence for the dependence of MM cells upon stromal
cells from the bone marrow is mostly indirect. A common
way to demonstrate the contribution of a particular cell to a
specific function would be cell ablation. Thus, knockout of
the T cell receptor (TCR) would result in a lack of mature T
cells and is a clear-cut demonstration of the subsequent lack
of cellular immunity. A technology for bone marrow
stromal cell ablation is unavailable. There are only
circumstantial indications for the dependence of MM cells
on the bone marrow stroma. Moreover, as will emerge from
the following description of experimental systems used to
study this issue, most information is based on cell cultures.
Several animal models have been constructed for the study
of MM. In the mouse, subcutaneous tumors are often used
to study the disease. These, however, are rather remote
from the human situation. In contrast, the 5T22 tumor
model allows for the growth of MM cells within the bone
marrow compartment, and therefore this model is the
closest to human MM [96]. Immunodefficient mouse
models are employed in order to enable the study of human
MM cells. One example is the transplantation of human
bone into these mice, followed by intra-bone implantation
of MM cells [43]. While this model allows the study of
human MM cells in vivo, it lacks compatibility in hormonal
and cytokine signaling. Furthermore, the model does not
include human immune cells, such as T regulatory cells,
which are thought to contribute to the pathogenesis of MM.
The general view of MM is that the tumor cells adhere to
the bone marrow stroma, and are dependent for their survival
and proliferation on growth factors elaborated in the bone
marrow microenvironment. Subsequent to their adhesion to
the stroma, MM cells induce the secretion of various
cytokines, thereby enhancing osteoclastogenesis and damag-
ing osteobalstogenesis. In MM the predominance of the
osteoclastic activity brings about bone lesions and fractures,
further enhancing the elaboration of cytokines and enhancing
MM cell proliferation. These general features of MM are
further elaborated on below.
Adhesion of MM Cells to Bone Marrow Stromal Cells
The adhesion of MM cells to the mesenchymal stroma of the
bone marrow has been suggested as being crucial for the
proliferation of MM cells. Interference with adhesion
processes reduced MM growth, secretion of interleukin
(IL)-6 and osteolysis. MM cell lines, co-cultured with a
stromal cell line, are often used to study the interactions
between MM cells and the stroma. The 5TGM1 mouse
myeloma was shown to adhere to the stromal cell line
ST2 in one such study. This adherence is mediated by
α4β1i n t e g r i ne x p r e s s e db yt h em y e l o m ac e l ll i n ea n d
VCAM-1 found on the surface of the stromal cell [97].
The interaction between the myeloma and stromal cell
caused release of bone resorbing activity. The role of
α4β1 integrin was further substantiated in an in vivo
study, in which the 5TGM1 myeloma was transplanted
into mice, thereby causing osteolysis. This bone damage
could be reduced by treatment with antibodies to α4[ 98].
An additional integrin, VLA-4, expressed by human
primary MM cells or MM cell lines, made a major
contribution to the in vitro interaction of these MM cells
with fibronectin and VCAM-1 [99]( F i g .4). The adhesion
of MM cell lines, from both humans and mice, was shown
to be down regulated by agonists of the peroxisome
proliferators-activated receptor (PPAR)γ [100]. Adhesion
interactions, described in this section, are common to
many cellular systems. It is therefore not surprising that
s o m eo ft h e ma r ea l s os h a r e db yH S C s .
Drug Resistance Conferred on MM Cells Interacting
with Stromal Cells
Although alkylating drugs and authologous bone marrow
transplantation, as well as newly developed drugs such as
bortezomib, thalidomide and lenalidomide, improve the
health status of MM patients, there is thus far no treatment
regimen that results in a complete cure. MM patients often
exhibit resistance to drugs and this may in part be due to the
adhesive interactions of MM cells with the stroma, which
render these cells resistant to the effect of chemotherapeutic
agents. The direct adherence of human MM cell lines to
primary bone marrow stroma increased their resistance to a
Fig. 4 MM cells adhere to bone marrow stromal cells
Myeloma microenvironment versus stem cell niche 21topoisomerase II inhibitor, mitoxantrone. Such resistance
could also be conferred by soluble factors released during
the interactions between the MM cell line and the stroma
[101]. Similar stromal effects mediated by direct interac-
tions and soluble factors conferred resistance of MM cell
lines to the apoptosis induced by the Apo2 ligand/TRAIL
[102] (Fig. 5) (see below, under “inhibitory cytokines”).
The protective effect of the stroma is not general; whereas
stromal cells protect a MM cell line from dexamethasone,
the same stroma caused increased sensitivity to doxorubicin
and melphalan [103]. The resistance granted is due in part
to direct cell-to-cell interactions through adhesive interac-
tions but is also conferred by the soluble factors IGF-I and
IGF-II [104].
Role of Stimulatory Cytokines in MM
IL-6, which is one product of bone marrow stromal cells
but is expressed by many other cell types, is thought to be a
major contributor to MM cell survival and growth in the
bone marrow microenvironment. In vitro data show that
mouse plasmacytomas are often IL-6 dependent. However,
cell lines that are IL-6 independent, in that they do not
require for in vitro growth the addition of the cytokine, are
rather prevalent. Some of the latter strive on autocrine
secretion of IL-6, while others have a modified, constitu-
tively active, IL-6 signaling cascade. Human MM cells that
are otherwise IL-6 dependent, seem to lose this dependence
when in contact with bone marrow stromal cells [105].
Toll-like receptor ligands mediate survival of MM cells by
inducing autocrine secretion of IL-6 [106]. Human MM
cells isolated from the bone marrow are growth stimulated
in vitro by IL-6. Their survival is however limited in time.
The lack of plasmacytoma development in mice, that are
IL-6 deficient, strongly supports the critical role of this
molecule in the emergence of this disease [107]. Yet,
therapeutic attempts using antibodies to this cytokine have
not yielded promising results probably due to the multitude
of growth factors that could compensate for the absence of
IL-6. It is noteworthy that IL-6 has a direct differentiation
inducing effect on HSCs and it effectively synergizes with
other cytokines to induce massive differentiation. In
contrast, it is not known to promote HSC renewal and is
not listed amongst the molecules that form the self-renewal
niche for HSCs.
Several other cytokines have been implicated as growth
factors for MM cells (Fig. 6). These include IL-11, insulin
like growth factor (IGF)-1, IL-3 [108], leptin [109], and
hedgehog (hh) [110, 111]. It remains to be determined how
each of these molecules contributes to the survival of
myeloma cells within the bone marrow compartment.
Analysis of intracellular signaling events activated in MM
cells, or evoked in them by the growth factors on which
they are dependent, indicated a role for several intracellular
signaling cascades. These include PI3K, JAK/STAT, Raf
and MEK/ERK and NFkB pathways (Fig. 6) (reviewed by
[7]). Newly added signaling cascades are the mTORC1 and
MTORC2 pathways, which are known to regulate normal
cell survival and growth and are activated in many cancers.
The molecule DEPTOR suppresses mTORC kinase activity
and is therefore expressed at a low level in tumors. By
contrast, in a subset of MM, DEPTOR is highly expressed
[112]. Similarly to HSCs, the migration of MM cells is
influenced by the SDF-1/CXCR4 axis [113].
Role of Inhibitory Cytokines in MM
Apoptosis is a mode by which cells are killed physiolog-
ically in a manner that maintains the intracellular constit-
uents within membranal particles removed by phagocytosis.
This ensures that cells are removed from the organism
without spilling intracellular molecules that could cause
inflammation. Agents that cause apoptosis of MM cells
should therefore be considered as possible drugs. Tumor
necrosis factors (TNFs) are such death inducing molecules.
Fig. 6 IL-6 is a major survival and growth factor for MM cells but
other cytokines also affect MM cell survival by evoking intracellular
signaling cascades
Fig. 5 Adhesion of MM cells to stroma protects the tumor cells from
apoptosis
22 D. ZiporiTNF related apoptosis-inducing ligand (TRAIL), also called
Apo2 ligand (Apo2L), interacts with surface receptors to
generate a proapoptotic signal through interactions of the
receptor intracellular death domains with adaptor proteins
that activate proteolytic caspases. TRAIL/Apo2L has been
reported to overcome drug resistance of MM cell lines, as
well as MM tumor cells obtained from patients [114]
(Fig. 5). In addition to its direct effect on MM cells, it has
been suggested that TRAIL kills osteoblasts; untreated
osteoblasts were resistant to TRAIL, while osteoblast first
incubated with MM cells were killed by this molecule
[115]. The interactions between MM cells and the stroma,
are also affected by decorin, which is a small leucine-rich
proteoglycan. Its elimination from the stromal osteoblasts
increased the growth of MM cells by inhibiting several
pathways that otherwise contribute to myeloma progression
(Fig. 7)[ 116]. Activin A, a member of the TGFβ
superfamily, is expressed by mouse and human bone
marrow stromal cells. This molecule has a dual inhibitory
effect on MM cells (Fig. 8). Firstly, activin A causes a
block in cell cycle progression [117]. Secondly, this
molecule is a competitive antagonist of IL-6 [118, 119].
Thus, the molecule kills MM cells that are IL-6 dependent
through both mechanisms, and would also affect MM cells
that are IL-6 independent by directly affecting their cell
cycle progression.
The stroma is apparently a supportive niche for MM
cells. Therefore the finding that a stromal factor, activin A,
is capable of mediating MM cell death, is seemingly a
contradiction. However, the case may be that in normal
bone marrow, the balance between activin A and IL-6 is in
favor of the former, while in MM the titer of IL-6 is high
enough to overcome the inhibitory function of activin A.
Indeed, overdoses of IL-6 overcome the in vitro killing
effect of activin A [118]. The latter was also demonstrated
to inhibit plasmacytoma tumor development in vivo [120].
It is noteworthy that neither of the above listed inhibitors
have been implicated as a major player in the HSC self-
renewal process.
Osteoclastogenesis Mediated by MM Cells
The osteolysis occurring in MM patients is probably due to
the presence of MM cells within the bone cavities. MM
cells were shown to induce the expression of the receptor
activator of NF-kB ligand (RANKL), a major osteoclast
activator, in bone marrow stromal cells (Fig. 9)[ 121, 122].
Moreover, these cells suppress the expression of osteopro-
tegerin (OPG), a RANKL antagonist. This last finding was
recently used in an in vivo disease model. A MM cell line
transplanted into β2mNOD/SCID mice developed a bone
Fig. 9 Several MM cell induced functions lead to osteoclast
activation
Fig. 8 The stromal cell release the TGFβ cytokine activin A causes
apoptosis of myeloma cells. Additional cytokines that take part in the
interactions between the MM cell and the stroma are indicated
Fig. 7 Decorin, a stroma cell surface proteoglycan elicits several
functions that negatively regulate MM cell survival within the bone
marrow
Myeloma microenvironment versus stem cell niche 23marrow disease involving an increase in osteoclast number
and bone loss. Upon treatment with multipotent stromal
cells, (MSC) transduced with hOPG, bone loss was
diminished [123]. MM may thus involve an imbalance
between osteoclast stimulation, mediated by RANKL and
MIP1α, and inhibitory agents such as OPG and DKK1. In
addition, the occupancy of the bone marrow with MM cells
causes an accumulation of molecules that potentially
augment osteoclastogenesis, including CSF-1, IL-6. Indeed
it was found that not only RANKL but also MM cells
themselves up-regulate the expression of IL-6 and IL-11 by
bone marrow stromal cells [124]. These findings suggest
that in fact the progression of osteolysis would enhance
MM growth and dissemination. In line with this conclusion,
the treatment of diseased mice with inhibitors of osteoclast
activity, reduced bone resorption and also inhibited myeloma
growth [125]. One component in the mediation of osteolysis
are matrix-degrading proteases. Overall, increased osteoclas-
togenesis causes bone damage, along side with the secretion
of cytokines that promote further myeloma growth and
spread (Fig. 10).
Expression and Activity of Proteinases in MM
A host of proteases have been reported to be expressed in
MM. These include the matrix metalloprotease (MMP)-1,
MMP-2, MMP-7, MMP-8, MMP-9 and MMP-13, as well
as urokinase plasminogen activator (uPA). Several of the
MMPs degrade collagen, a major constituent of the bone
matrix. uPA cleaves non-collagenous proteins. Therefore,
the collective expression of these molecules may contribute
to bone lesions in MM. in vitro experiments using both
primary myeloma and MM cell lines cultured with
osteoblasts isolated from human bone marrow showed that
MM cells induce the expression of MMP-1, MMP-2 and
uPA in the osteoblasts [126, 127]. Stromal cells suppress
plasma cell IgG production by secreting MMPs that
degrade the chemokine ligands CCL2 and CCL7, such that
antagonistic degradation products are produced [128].
The Status of the Bone Marrow Mesenchymal Stroma
and Osteoblasts in MM
While osteoclastogenesis is an overt occurrence in MM due
to the bone lesions, the possible involvement of osteoblasts
in the course of the disease is less pronounced. However,
several reports indicate that osteoblasts are targeted in MM.
As has been indicated above, cultured MM cells induce the
secretion of a variety of cytokines by the mesenchymal
stroma and by osteoblastic cells in particular. In addition,
protease expression is augmented in the stroma. A number
of studies point to a possible damage caused to osteoblasts
by MM cells. These experiments imply that the stroma in
MM maybe defective. This could be due to the effect of the
MM cells themselves. Otherwise, primary defects in the
stroma could contribute to the emergence of the disease.
The question raised in both cases is whether the bone
marrow stroma in MM patients is deficient. Analysis of
adhesion molecules expressed by MM stroma, compared to
that of normal controls, did not reveal differences.
Adhesion of MM cell lines to stroma from patients and
normal individuals was shown to be similar [129]. Other
studies examined the properties of MSCs. One set of data
showed identity in differentiation potential between MM
derived and normal MSCs [130, 131] whereas another
study detected a deficient capacity to osteoblastic differen-
tiation of MM derived MSCs [132]. The latter function was
examined by Pevsner-Fischer et al., and was found to be
intact in MM MSCs (unpublished observations). This issue
is therefore unresolved and further studies are needed. A
study using comparative genomic hybridization, indicated
that stromal cells from MM patients, show genomic
imbalances that were not observed in stroma from normal
controls [133]. It remains to be seen whether these
occurrences affect MSC biological functions.
Conclusions
The discussion above highlighted the major features of the
HSC niche that maintains the stem cell phenotype. This
niche is made of several cellular elements, which are still
poorly characterized. Therefore, a clear conclusion as to
whether HSCs and MM TIC share the same supportive
stromal cell type is premature. It has recently been
suggested that macrophages protect MM cells from apo-
ptosis. These cells are an ample source of cytokines and if
anything, their presence in the HSC niche would promote
differentiation, rather than renewal. More importantly, it
Fig. 10 MM cells induce osteolysis and the release of cytokines that
further promote MM cell survival and growth
24 D. Ziporiseems that the macrophages that promote MM survival, are
tumor specific cells and may differ from normal macro-
phages [134]. Thus, the nature of the cells that form the
MM microenvironment and those that create the HSC niche
is still an open question. However, based on current
knowledge the microenvironment of MM tumor seems to
markedly differ from that of the normal bone marrow.
In contrast to the vagueness in regards to the exact cell
types that form the MM environment versus those that
make the HSC niche, it is obvious that HSCs and MM TICs
differ markedly in their cytokine requirements. The above
summary of cytokines, that affect HSCs self-renewal,
highlighted the importance of molecules that antagonize
differentiation processes. For example, TGFβs reduce
differentiation and angiopoietin and thrombopoietin keep
HSCs quiescent. Thus, such molecules block the option for
differentiation and consequently allow stem cell renewal to
occur. The vast majority of MM cells are fully mature
plasma-like cells that secrete antibodies. These are end cells
in the differentiation cascade and therefore the issue of
blockade of differentiation does not apply in MM. It is
often argued that most of the MM plasma cells are
quiescent and therefore do not contribute to the increase
in tumor load. However, TICs are expected to be quiescent
and indeed most MM plasma-like cells were found to
contribute to tumor formation in a human/mouse model.
Certainly, in the mouse, as few as 100 plasmacytoma cells
may form a tumor under the skin of Nude mice [120]. The
survival of MM cells is dependent on several growth
factors, the major one being IL-6. This molecule makes
little, if any, contribution to the HSC niche. MM cannot be
induced in IL-6 deficient mice while these mice do not lack
HSCs. A major contribution to MM cell survival and
growth within the bone marrow compartment is ascribed to
osteoclastogenesis, the subsequent osteolysis and release of
inflammatory cytokines. The latter promote MM cell
survival and growth and allow the spread of the disease
within the bone marrow. The complete opposite is true for
the HSC. Increased osteoclastogenesis generates signals
that drive HSCs away from their niches. It is therefore
concluded that there is no solid evidence for any true
similarity between HSCs and MM TICs, and these cell
types represent distinct biological entities.
One question raised is whether the information available,
to date, provides an explanation for the residence of MM
cells within the bone marrow. The molecules that have been
detailed above as major players in MM, like the adhesion
pair VLA-4/VCAM-1 and the cytokine IL-6, are clearly not
bone marrow specific. It follows that the specificity in bone
marrow localization should be sought in the bone itself.
Indeed, osteoclasts are clearly affected by MM, but
compelling evidence for the absolute necessity of these
cells for the bone marrow localization and retention of MM
cells is not available. It would be of importance to examine
mice deficient in osteoclasts to clarify this point.
Other candidate cells contributing to the MM TIC
microenvironment are the osteoblasts. These cells may be
modified in the myelomatous bone compartment, and may
therefore serve as a docking site for the malignant cells.
However, data available thus far does not support this
possibility. It seems that too little effort has been put in the
analysis of stromal cells from MM patients. A few studies
suggest that MM stroma diverges from normal, while in
other studies the MM stroma was found to be normal.
Further analysis is needed to resolve this issue.
Acknowledgments The author is indebted to the Helen and Martin
Kimmel Institute for Stem Cell Research and the M.D. Moross Institute
forCancerResearch,attheWeizmannInstitute,theGabrielleRichCenter
for TransplantationBiology and the support of the Legacy Heritage Fund
of New York. DZ is an incumbent of the Joe and Celia Weinstein
Professorial Chair at the Weizmann Institute of Science.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC (2004)
Advances in biology of multiple myeloma: clinical applications.
Blood 104(3):607–618
2. Edwards CM, Zhuang J, Mundy GR (2008) The pathogenesis of
the bone disease of multiple myeloma. Bone 42(6):1007–1013
3. Pagnucco G, Cardinale G, Gervasi F (2004) Targeting multiple
myeloma cells and their bone marrow microenvironment. Ann
NY Acad Sci 1028:390–399
4. Ribatti D, Nico B, Vacca A (2006) Importance of the bone
marrow microenvironment in inducing the angiogenic response
in multiple myeloma. Oncogene 25(31):4257–4266
5. Kyle RA, Rajkumar SV (2008) Multiple myeloma. Blood 111
(6):2962–2972
6. Podar K, Chauhan D, Anderson KC (2009) Bone marrow
microenvironment and the identification of new targets for
myeloma therapy. Leukemia 23(1):10–24
7. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson
KC (2007) Understanding multiple myeloma pathogenesis in the
bone marrow to identify new therapeutic targets. Nat Rev Cancer
7(8):585–598
8. Mitsiades CS, Mitsiades NS, Richardson PG, Munshi NC,
Anderson KC (2007) Multiple myeloma: a prototypic disease
model for the characterization and therapeutic targeting of
interactions between tumor cells and their local microenvironment.
J Cell Biochem 101(4):950–968
9. Ocio EM, Mateos MV, Maiso P, Pandiella A, San-Miguel JF
(2008) New drugs in multiple myeloma: mechanisms of action
and phase I/II clinical findings. Lancet Oncol 9(12):1157–1165
10. Sekimoto E, Ozaki S, Ohshima T, Shibata H, Hashimoto T, Abe
M et al (2007) A single-chain Fv diabody against human
leukocyte antigen-A molecules specifically induces myeloma
cell death in the bone marrow environment. Cancer Res 67
(3):1184–1192
Myeloma microenvironment versus stem cell niche 2511. Normile D (2002) proliferation. Common control for cancer,
stem cells. Science 298(5600):1869
12. Dick JE (2003) Breast cancer stem cells revealed. Proc Natl
Acad Sci USA 100(7):3547–3549
13. Owens DM, Watt FM (2003) Contribution of stem cells and
differentiated cells to epidermal tumours. Nat Rev Cancer 3
(6):444–451
14. Marx J (2003) Cancer research. Mutant stem cells may seed
cancer. Science 301(5638):1308–1310
15. Singh SK, Clarke ID, Hide T, Dirks PB (2004) Cancer stem cells
in nervous system tumors. Oncogene 23(43):7267–7273
16. Couzin J (2004) Cancer research. Proposed leukemia stem cell
encounters a blast of scrutiny. Science 305(5686):929
17. HuntlyBJ,GillilandDG(2004)Blastsfromthepast:newlessonsin
stem cell biology from chronic myelogenousleukemia. CancerCell
6(3):199–201
18. Bell DR, Van Zant G (2004) Stem cells, aging, and cancer:
inevitabilities and outcomes. Oncogene 23(43):7290–7296
19. Jamieson CH, Weissman IL, Passegue E (2004) Chronic versus
acute myelogenous leukemia: a question of self-renewal. Cancer
Cell 6(6):531–533
20. Scadden DT (2004) Cancer stem cells refined. Nat Immunol 5
(7):701–703
21. Daley GQ (2004) Chronic myeloid leukemia: proving ground for
cancer stem cells. Cell 119(3):314–316
22. Trounson A (2004) Stem cells, plasticity and cancer—
uncomfortable bed fellows. Development 131(12):2763–2768
23. Beachy PA, Karhadkar SS, Berman DM (2004) Tissue repair and
stem cell renewal in carcinogenesis. Nature 432(7015):324–331
24. Radtke F, Clevers H (2005) Self-renewal and cancer of the gut:
two sides of a coin. Science 307(5717):1904–1909
25. Reya T, Clevers H (2005) Wnt signalling in stem cells and
cancer. Nature 434(7035):843–850
26. Fomchenko EI, Holland EC (2005) Stem cells and brain cancer.
Exp Cell Res 306(2):323–329
27. Clevers H (2005) Stem cells, asymmetric division and cancer.
Nat Genet 37(10):1027–1028
28. Huntly BJ, Gilliland DG (2005) Leukaemia stem cells and the
evolution of cancer-stem-cell research. Nat Rev Cancer 5
(4):311–321
29. Bissell MJ, Labarge MA (2005) Context, tissue plasticity, and
cancer:aretumorstemcellsalsoregulatedbythemicroenvironment?
Cancer Cell 7(1):17–23
30. Weissman I (2005) Stem cell research: paths to cancer therapies
and regenerative medicine. Jama 294(11):1359–1366
31. Dean M, Fojo T, Bates S (2005) Tumour stem cells and drug
resistance. Nat Rev Cancer 5(4):275–284
32. Elrick LJ, Jorgensen HG, Mountford JC, Holyoake TL (2005)
Punish the parent not the progeny. Blood 105(5):1862–1866
33. Tan BT, Park CY, Ailles LE, Weissman IL (2006) The cancer
stem cell hypothesis: a work in progress. Lab Invest 86
(12):1203–1207
34. Jordan CT (2006) Searching for leukemia stem cells—not yet the
end of the road? Cancer Cell 10(4):253–254
35. Vescovi AL, Galli R, Reynolds BA (2006) Brain tumour stem
cells. Nat Rev Cancer 6(6):425–436
36. Dick JE (2008) Stem cell concepts renew cancer research. Blood
112(13):4793–4807
37. Bergsagel DE, Valeriote FA (1968) Growth characteristics of a
mouse plasma cell tumor. Cancer Res 28(11):2187–2196
38. Matsui W, Huff CA, Wang Q, Malehorn MT, Barber J, Tanhehco
Y et al (2004) Characterization of clonogenic multiple myeloma
cells. Blood 103(6):2332–2336
39. Matsui W, Wang Q, Barber JP, Brennan S, Smith BD, Borrello I
et al (2008) Clonogenic multiple myeloma progenitors, stem cell
properties, and drug resistance. Cancer Res 68(1):190–197
40. Pilarski LM, Belch AR (2002) Clonotypic myeloma cells able to
xenograft myeloma to nonobese diabetic severe combined
immunodeficient mice copurify with CD34 (+) hematopoietic
progenitors. Clin Cancer Res 8(10):3198–3204
41. Pilarski LM, Hipperson G, Seeberger K, Pruski E, Coupland
RW, Belch AR (2000) Myeloma progenitors in the blood of
patients with aggressive or minimal disease: engraftment and
self-renewal of primary human myeloma in the bone marrow of
NOD SCID mice. Blood 95(3):1056–1065
42. Karp JE, Burke PJ, Saylor PL, Humphrey RL (1984) Correlation
of proliferative and clonogenic tumor cells in multiple myeloma.
Cancer Res 44(9):4197–4200
43. Tassone P, Neri P, Carrasco DR, Burger R, Goldmacher VS,
Fram R et al (2005) A clinically relevant SCID-hu in vivo model
of human multiple myeloma. Blood 106(2):713–716
44. Ferrone S, Sconocchia G (2005) A clinically relevant mouse
model of human multiple myeloma? Blood 106:388–389
45. Laronne-Bar-On A, Zipori D, Haran-Ghera N (2008) Increased
regulatory versus effector T cell development is associated with
thymus atrophy in mouse models of multiple myeloma. J Immunol
181(5):3714–3724
46. Kirshner J, Thulien KJ, Martin LD, Debes Marun C, Reiman T,
Belch AR et al (2008) A unique three-dimensional model for
evaluating the impact of therapy on multiple myeloma. Blood 112
(7):2935–2945
47. Katz BZ (2008) Side populations—following the footprints of
the elusive multiple myeloma stem cells? Leuk Lymphoma 49
(9):1657–1658
48. Brennan SK, Matsui W (2009) Cancer stem cells: controversies
in multiple myeloma. J Mol Med Sep 17
49. Ghosh N, Matsui W (2009) Cancer stem cells in multiple
myeloma. Cancer Lett 277(1):1–7
50. Zipori D (2004) The nature of stem cells: state rather than entity.
Nat Rev Genet 5(11):873–878
51. Zipori D (2009) Biology of stem cells and the molecular basis of
the stem state. In: Turksen K (ed) Stem cell biology and
regenerative medicine. Series. Humana Press, Springer
52. Yaccoby S, Barlogie B, Epstein J (1998) Primary myeloma cells
growing in SCID-hu mice: a model for studying the biology and
treatmentofmyelomaandits manifestations.Blood92(8):2908–2913
53. Yaccoby S, Epstein J (1999) The proliferative potential of
myeloma plasma cells manifest in the SCID-hu host. Blood 94
(10):3576–3582
54. Kelly PN, Dakic A, Adams JM, Nutt SL, Strasser A (2007)
Tumor growth need not be driven by rare cancer stem cells.
Science 317(5836):337
55. Wilson A, Laurenti E, Oser G, van der Wath RC, Blanco-Bose
W, Jaworski M et al (2008) Hematopoietic stem cells reversibly
switch from dormancy to self-renewal during homeostasis and
repair. Cell 135(6):1118–1129
56. Huff CA, Matsui W (2008) Multiple myeloma cancer stem cells.
J Clin Oncol 26(17):2895–2900
57. Basak GW, Srivastava AS, Malhotra R, Carrier E (2009) Multiple
myeloma bone marrow niche. Curr Pharm Biotechnol 10(3):345–346
58. Zipori D (1981) Cell interactions in the bone marrow
microenvironment: role of endogenous colony-stimulating
activity. J Supramol Struct Cell Biochem 17(4):347–357
59. Zipori D, Sasson T (1980) Adherent cells from mouse bone
marrow inhibit the formation of colony stimulating factor (CSF)
induced myeloid colonies. Exp Hematol 8(6):816–817
60. Xie T, Spradling AC (1998) Decapentaplegic is essential for the
maintenance and division of germline stem cells in the
Drosophila ovary. Cell 94(2):251–260
61. Lambertsen RH, Weiss L (1984) A model of intramedullary
hematopoietic microenvironments based on stereologic study of the
distribution of endocloned marrow colonies. Blood 63(2):287–297
26 D. Zipori62. Lord BI, Testa NG, Hendry JH (1975) The relative spatial
distributions of CFUs and CFUc in the normal mouse femur.
Blood 46(1):65–72
63. Schofield R (1978) The relationship between the spleen colony-
formingcell and the haemopoietic stem cell. BloodCells 4(1–2):7–25
64. Friedenstein AJ, Chailakhjan RK, Lalykina KS (1970) The
development of fibroblast colonies in monolayer cultures of
guinea-pig bone marrow and spleen cells. Cell Tissue Kinet 3
(4):393–403
65. Friedenstein AJ, Chailakhyan RK, Latsinik NV, Panasyuk AF,
Keiliss-Borok IV (1974) Stromal cells responsible for transferring
the microenvironment of the hemopoietic tissues. Cloning in vitro
and retransplantation in vivo. Transplantation 17(4):331–340
66. SacchettiB,FunariA,MichienziS,DiCesareS,PiersantiS,Saggio
I et al (2007) Self-renewing osteoprogenitors in bone marrow
sinusoidscanorganizeahematopoieticmicroenvironment.Cell131
(2):324–336
67. Dexter TM, Allen TD, Lajtha LG (1977) Conditions controlling
the proliferation of haemopoietic stem cells in vitro. J Cell
Physiol 91(3):335–344
68. Calvi LM, Adams GB, Weibrecht KW, Weber JM, Olson DP,
Knight MC et al (2003) Osteoblastic cells regulate the
haematopoietic stem cell niche. Nature 425(6960):841–846
69. Kiel MJ, Yilmaz OH, Iwashita T, Terhorst C, Morrison SJ (2005)
SLAM family receptors distinguish hematopoietic stem and
progenitor cells and reveal endothelial niches for stem cells. Cell
121(7):1109–1121
70. Zhang J, Niu C, Ye L, Huang H, He X, Tong WG et al (2003)
Identification of the haematopoietic stem cell niche and control
of the niche size. Nature 425(6960):836–841
71. Williams DA, Rios M, Stephens C, Patel VP (1991) Fibronectin
and VLA-4 in haematopoietic stem cell-microenvironment
interactions. Nature 352(6334):438–441
72. Avecilla ST, Hattori K, Heissig B, Tejada R, Liao F, Shido K et
al (2004) Chemokine-mediated interaction of hematopoietic
progenitors with the bone marrow vascular niche is required
for thrombopoiesis. Nat Med 10(1):64–71
73. Stier S, Ko Y, Forkert R, Lutz C, Neuhaus T, Grunewald E et al
(2005) Osteopontin is a hematopoietic stem cell niche component
that negatively regulates stem cell pool size. J Exp Med 201
(11):1781–1791
74. Bhatia M, Bonnet D, Wu D, Murdoch B, Wrana J, Gallacher
L et al (1999) Bone morphogenetic proteins regulate the
developmental program of human hematopoietic stem cells. J
Exp Med 189(7):1139–1148
75. Peled A, Kollet O, Ponomaryov T, Petit I, Franitza S, Grabovsky
Vet al (2000) The chemokine SDF-1 activates the integrins LFA-
1, VLA-4, and VLA-5 on immature human CD34(+) cells: role
in transendothelial/stromal migration and engraftment of NOD/
SCID mice. Blood 95(11):3289–3296
76. Arai F, Hirao A, Ohmura M, Sato H, Matsuoka S, Takubo K et al
(2004) Tie2/angiopoietin-1 signaling regulates hematopoietic
stem cell quiescence in the bone marrow niche. Cell 118
(2):149–161
77. Fleming HE, Janzen V (2008) Lo Celso C, Guo J, Leahy KM,
Kronenberg HM, et al. Wnt signaling in the niche enforces
hematopoietic stem cell quiescence and is necessary to preserve
self-renewal in vivo. Cell Stem Cell 2(3):274–283
78. Yoshihara H, Arai F, Hosokawa K, Hagiwara T, Takubo K,
Nakamura Y et al (2007) Thrombopoietin/MPL signaling
regulates hematopoietic stem cell quiescence and interaction
with the osteoblastic niche. Cell Stem Cell 1(6):685–697
79. Toksoz D, Zsebo KM, Smith KA, Hu S, Brankow D, Suggs SV
et al (1992) Support of human hematopoiesis in long-term bone
marrow cultures by murine stromal cells selectively expressing
the membrane-bound and secreted forms of the human homolog
of the steel gene product, stem cell factor. Proc Natl Acad Sci
USA 89(16):7350–7354
80. Zhang CC, Lodish HF (2004) Insulin-like growth factor 2
expressed in a novel fetal liver cell population is a growth factor
for hematopoietic stem cells. Blood 103(7):2513–2521
81. Lane SW, Scadden DT, Gilliland DG (2009) The leukemic stem
cell niche: current concepts and therapeutic opportunities. Blood
114(6):1150–1157
82. Iwasaki H, Suda T (2009) Cancer stem cells and their niche.
Cancer Sci 100(7):1166–1172
83. Zipori D (1992) The renewal and differentiation of hemopoietic
stem cells. Faseb J 6(9):2691–2697
84. Zipori D (1990) Regulation of hemopoiesis by cytokines that restrict
options for growth and differentiation. Cancer Cells 2(7):205–211
85. Zipori D, Barda-Saad M (2001) Role of activin A in negative
regulation of normal and tumor B lymphocytes. J Leukoc Biol
69(6):867–873
86. Brawley C, Matunis E (2004) Regeneration of male germline
stem cells by spermatogonial dedifferentiation in vivo. Science
304(5675):1331–1334
87. Chen X, Mao Z, Liu S, Liu H, Wang X, Wu H, et al (2005)
Dedifferentiation of Adult Human Myoblasts Induced by CNTF
In Vitro. Mol Biol Cell Apr 20
88. Sharif A, Legendre P, Prevot V, Allet C, Romao L, Studler JM, et
al (2006) Transforming growth factor alpha promotes sequential
conversion of mature astrocytes into neural progenitors and stem
cells. Oncogene Oct 23
89. Matsumoto T, Kano K, Kondo D, Fukuda N, Iribe Y, Tanaka N
et al (2008) Mature adipocyte-derived dedifferentiated fat cells
exhibit multilineage potential. J Cell Physiol 215(1):210–222
90. Takahashi K, Yamanaka S (2006) Induction of pluripotent stem
cells from mouse embryonic and adult fibroblast cultures by
defined factors. Cell 126(4):663–676
91. Nakagawa M, Koyanagi M, Tanabe K, Takahashi K, Ichisaka T,
Aoi T et al (2008) Generation of induced pluripotent stem cells
without Myc from mouse and human fibroblasts. Nat Biotechnol
26(1):101–106
92. Hanna J, Markoulaki S, Schorderet P, Carey BW, Beard C, Wernig
M et al (2008) Direct reprogramming of terminally differentiated
mature B lymphocytes to pluripotency. Cell 133(2):250–264
93. Aoi T, Yae K, Nakagawa M, Ichisaka T, Okita K, Takahashi K et
al (2008) Generation of pluripotent stem cells from adult mouse
liver and stomach cells. Science 321(5889):699–702
94. Silva J, Barrandon O, Nichols J, Kawaguchi J (2008) Theunissen
TW. Smith A Promotion of reprogramming to ground state
pluripotency by signal inhibition PLoS Biol 6(10):e253
95. Conrad S, Renninger M, Hennenlotter J, Wiesner T, Just L,
Bonin M et al (2008) Generation of pluripotent stem cells from
adult human testis. Nature 456(7220):344–349
96. Vanderkerken K, De Raeve H, Goes E, Van Meirvenne S, Radl J,
Van Riet I et al (1997) Organ involvement and phenotypic
adhesion profile of 5 T2 and 5 T33 myeloma cells in the C57BL/
KaLwRij mouse. Br J Cancer 76(4):451–460
97. Michigami T, Shimizu N, Williams PJ, Niewolna M, Dallas SL,
Mundy GR et al (2000) Cell-cell contact between marrow stromal
cells and myeloma cells via VCAM-1 and alpha(4)beta(1)-integrin
enhances production of osteoclast-stimulating activity. Blood 96
(5):1953–1960
98. Mori Y, Shimizu N, Dallas M, Niewolna M, Story B, Williams
PJ et al (2004) Anti-alpha4 integrin antibody suppresses the
development of multiple myeloma and associated osteoclastic
osteolysis. Blood 104(7):2149–2154
99. Sanz-Rodriguez F, Ruiz-Velasco N, Pascual-Salcedo D, Teixido
J (1999) Characterization of VLA-4-dependent myeloma cell
adhesion to fibronectin and VCAM-1. Br J Haematol 107
(4):825–834
Myeloma microenvironment versus stem cell niche 27100. Wang LH, Yang XY, Zhang X, Farrar WL (2007) Inhibition of
adhesive interaction between multiple myeloma and bone
marrow stromal cells by PPARgamma cross talk with NF-
kappaB and C/EBP. Blood 110(13):4373–4384
101. Nefedova Y, Landowski TH, Dalton WS (2003) Bone marrow
stromal-derived soluble factors and direct cell contact contribute
to de novo drug resistance of myeloma cells by distinct
mechanisms. Leukemia 17(6):1175–1182
102. Perez LE, Parquet N, Shain K, Nimmanapalli R, Alsina M,
Anasetti C et al (2008) Bone marrow stroma confers resistance to
Apo2 ligand/TRAIL in multiple myeloma in part by regulating c-
FLIP. J Immunol 180(3):1545–1555
103. Cheung WC, Van Ness B (2001) The bone marrow stromal
microenvironment influences myeloma therapeutic response in
vitro. Leukemia 15(2):264–271
104. Xu F, Gardner A, Tu Y, Michl P, Prager D, Lichtenstein A (1997)
Multiple myeloma cells are protected against dexamethasone-
induced apoptosis by insulin-like growth factors. Br J Haematol
97(2):429–440
105. Chatterjee M, Honemann D, Lentzsch S, Bommert K, Sers C,
Herrmann P et al (2002) In the presence of bone marrow stromal
cells human multiple myeloma cells become independent of the
IL-6/gp130/STAT3 pathway. Blood 100(9):3311–3318
106. Bohnhorst J, Rasmussen T, Moen SH, Flottum M, Knudsen L,
Borset M et al (2006) Toll-like receptors mediate proliferation and
survival of multiple myeloma cells. Leukemia 20(6):1138–1144
107. Hilbert DM, Kopf M, Mock BA, Kohler G, Rudikoff S (1995)
Interleukin 6 is essential for in vivo development of B lineage
neoplasms. J Exp Med 182(1):243–248
108. Lee JW, Chung HY, Ehrlich LA, Jelinek DF, Callander NS,
Roodman GD et al (2004) IL-3 expression by myeloma cells
increases both osteoclast formation and growth of myeloma
cells. Blood 103(6):2308–2315
109. Caers J, Deleu S, Belaid Z, De Raeve H, Van Valckenborgh E,
De Bruyne E et al (2007) Neighboring adipocytes participate in
the bone marrow microenvironment of multiple myeloma cells.
Leukemia 21(7):1580–1584
110. Dierks C, Grbic J, Zirlik K, Beigi R, Englund NP, Guo GR et al
(2007) Essential role of stromally induced hedgehog signaling in
B-cell malignancies. Nat Med 13(8):944–951
111. Peacock CD, Wang Q, Gesell GS, Corcoran-Schwartz IM, Jones
E, Kim J et al (2007) Hedgehog signaling maintains a tumor
stem cell compartment in multiple myeloma. Proc Natl Acad Sci
USA 104(10):4048–4053
112. Peterson TR, Laplante M, Thoreen CC, Sancak Y, Kang SA,
Kuehl WM et al (2009) DEPTOR is an mTOR inhibitor
frequently overexpressed in multiple myeloma cells and required
for their survival. Cell 137(5):873–886
113. Gazitt Y, Akay C (2004) Mobilization of myeloma cells involves
SDF-1/CXCR4 signaling and downregulation of VLA-4. Stem
Cells 22(1):65–73
114. Mitsiades CS, Treon SP, Mitsiades N, Shima Y, Richardson P,
Schlossman R et al (2001) TRAIL/Apo2L ligand selectively
induces apoptosis and overcomes drug resistance in multiple
myeloma: therapeutic applications. Blood 98(3):795–804
115. Tinhofer I, Biedermann R, Krismer M, Crazzolara R, Greil R
(2006) A role of TRAIL in killing osteoblasts by myeloma cells.
FASEB J 20(6):759–761
116. Li X, Pennisi A, Yaccoby S (2008) Role of decorin in the
antimyeloma effects of osteoblasts. Blood 112(1):159–168
117. Zauberman A, Oren M, Zipori D (1997) Involvement of p21(WAF1/
Cip1), CDK4 and Rb in activin A mediated signaling leading to
hepatoma cell growth inhibition. Oncogene 15(14):1705–1711
118. Brosh N, Sternberg D, Honigwachs-Sha’anani J, Lee BC, Shav-Tal
Y, Tzehoval E et al (1995) The plasmacytoma growth inhibitor
restrictin-P is an antagonist of interleukin 6 and interleukin 11.
Identification as a stroma-derived activin A. J Biol Chem 270
(49):29594–29600
119. Sternberg D, Honigwachs-sha’anani J, Brosh N, Malik Z, Burstein
Y, Zipori D (1995) Restrictin-P/stromal activin A, kills its target
cells via an apoptotic mechanism. Growth Factors 12(4):277–287
120. Shoham T, Sternberg D, Brosh N, Krupsky M, Barda-Saad M,
Zipori D (2001) The promotion of plasmacytoma tumor growth
by mesenchymal stroma is antagonized by basic fibroblast
growth factor induced activin A. Leukemia 15(7):1102–1110
121. Roux S, Meignin V, Quillard J, Meduri G, Guiochon-Mantel A,
Fermand JP et al (2002) RANK (receptor activator of nuclear
factor-kappaB) and RANKL expression in multiple myeloma. Br
J Haematol 117(1):86–92
122. Sezer O, Heider U, Zavrski I, Kuhne CA, Hofbauer LC (2003)
RANK ligand and osteoprotegerin in myeloma bone disease.
Blood 101(6):2094–2098
123. Rabin N, Kyriakou C, Coulton L, Gallagher OM, Buckle C,
Benjamin R et al (2007) A new xenograft model of myeloma
bone disease demonstrating the efficacy of human mesenchymal
stem cells expressing osteoprotegerin by lentiviral gene transfer.
Leukemia 21(10):2181–2191
124. Giuliani N, Colla S, Morandi F, Rizzoli V (2004) The RANK/
RANKligandsystemisinvolvedininterleukin-6andinterleukin-11
up-regulation by human myeloma cells in the bone marrow
microenvironment. Haematologica 89(9):1118–1123
125. Yaccoby S, Pearse RN, Johnson CL, Barlogie B, Choi Y, Epstein
J (2002) Myeloma interacts with the bone marrow microenvi-
ronment to induce osteoclastogenesis and is dependent on
osteoclast activity. Br J Haematol 116(2):278–290
126. Hecht M, Heider U, Kaiser M, von Metzler I, Sterz J, Sezer O
(2007) Osteoblasts promote migration and invasion of myeloma
cells through upregulation of matrix metalloproteinases, uroki-
nase plasminogen activator, hepatocyte growth factor and
activation of p38 MAPK. Br J Haematol 138(4):446–458
127. Hecht M, von Metzler I, Sack K, Kaiser M, Sezer O (2008)
Interactions of myeloma cells with osteoclasts promote tumour
expansion and bone degradation through activation of a complex
signalling network and upregulation of cathepsin K, matrix
metalloproteinases (MMPs) and urokinase plasminogen activator
(uPA). Exp Cell Res 314(5):1082–1093
128. Rafei M, Hsieh J, Fortier S, Li M, Yuan S, Birman E et al (2008)
Mesenchymal stromal cell-derived CCL2 suppresses plasma cell
immunoglobulin production via STAT3 inactivation and PAX5
induction. Blood 112(13):4991–4998
129. Faid L, Van Riet I, De Waele M, Facon T, Schots R, Lacor P et al
(1996) Adhesive interactions between tumour cells and bone
marrow stromal elements in human multiple myeloma. Eur J
Haematol 57(5):349–358
130. Arnulf B, Lecourt S, Soulier J, Ternaux B, Lacassagne MN,
Crinquette A et al (2007) Phenotypic and functional character-
ization of bone marrow mesenchymal stem cells derived from
patients with multiple myeloma. Leukemia 21(1):158–163
131. Giuliani N, Mangoni M, Rizzoli V (2009) Osteogenic differentia-
tion of mesenchymal stem cells in multiple myeloma: identification
of potential therapeutic targets. Exp Hematol 37(8):879–886
132. Corre J, Mahtouk K, Attal M, Gadelorge M, Huynh A, Fleury-
Cappellesso S et al (2007) Bone marrow mesenchymal stem cells
are abnormal in multiple myeloma. Leukemia 21(5):1079–1088
133. Garayoa M, Garcia JL, Santamaria C, Garcia-Gomez A, Blanco JF,
Pandiella A et al (2009) Mesenchymal stem cells from multiple
myelomapatientsdisplaydistinctgenomicprofileascomparedwith
those from normal donors. Leukemia 23(8):1515–1527
134. Zheng Y, Cai Z, Wang S, Zhang X, Qian J, Hong S, et al (2009)
Macrophages are an abundant component of myeloma microen-
vironment and protect myeloma cells from chemotherapy drug-
induced apoptosis. Blood 114(17):3625–3628
28 D. Zipori